Takeaways included updates from the CheckMate 816 study, advances in technology, the role of metabolites and mobile CT screening in predicting cancer risk, and the importance of biomarkers for guiding optimal treatment. Read more
Drs. Joelle Fathi and Mahdi Sheikh summarize the growing body of evidence that shows quitting smoking after diagnosis improves survival. Read more
The combination treatment is the first and only regimen to show a survival benefit that surpasses the current standard of care for EGFR-mutated lung cancer. Read more
A new genetics study aims to collect data from 10,000 participants diagnosed with lung cancer to improve future outcomes and enhance research. Read more
FDA issues draft guidance on the use of AI for biological and drug product submissions, China’s NMPA grants priority review for the combination of savolitinib and osimertinib, and nivolumab and hyaluronidase-nvhy receive FDA approval for subcutaneous injection. Read more
Emerging Biomarkers Have Potential to Refine Patient Selection, Improve Immunotherapy Strategies
+more
Drs. Marina Chiara Garassino, Sulin Wu, and Faith Abodunrin offer insights from the RELATIVITY-104 and GALAXIES Lung-201 Trials. Read more
Heidi Nafman-Onda, founder of The White Ribbon Project, shares her experience discovering and grappling with the long-term effects of radiation therapy and addresses the need for coordinated survivorship care. Read more
During the opening plenary session at the 2024 Asia Conference on Lung Cancer, experts offered their perspectives on clinical trials, combination therapies, and research initiatives. Read more
Promising results from the phase III IMforte trial reveal a potential first-line therapy for patients with ES-SCLC. Read more
The US FDA approves ensartinib for ALK-positive NSCLC and provides an updated regulatory review of subcutaneous amivantamab. Read more